|Bid||33.260 x 1800|
|Ask||33.270 x 9900|
|Day's Range||33.195 - 33.450|
|52 Week Range||29.830 - 35.380|
|PE Ratio (TTM)||27.97|
|Dividend & Yield||1.28 (3.84%)|
|1y Target Est||N/A|
Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.
In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.
Giving credit where credit is due, I do think Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock looks stronger than it did just a couple of quarters ago. VRX stock has still declined 1.5% so far this year, but the narrative surrounding the company has certainly changed. On the Q2 conference call, Valeant management made a big deal of the fact that 73% of Q2 revenue came from Bausch & Lomb and the Salix business.